Is SBTX.L undervalued or overvalued?

As of 2025-03-15, the Intrinsic Value of SkinBioTherapeutics PLC (SBTX.L) is (3,987.43) GBP. This SBTX.L valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 24.50 GBP, the upside of SkinBioTherapeutics PLC is -16,375.20%. This means that SBTX.L is overvalued by 16,375.20%.

The range of the Intrinsic Value is (11,087.02) - (2,441.39) GBP

Note: result may not be accurate due to the invalid valuation result of DCF model.

	Range	Selected	Upside
a
DCF (Growth 5y)	(11,087.02) - (2,441.39)	(3,987.43)	-16375.2%
DCF (Growth 10y)	(50,463.84) - (246,668.51)	(85,497.46)	-349069.2%
DCF (EBITDA 5y)	(841.12) - (1,094.09)	(1,234.50)	-123450.0%
DCF (EBITDA 10y)	(17,974.46) - (25,212.06)	(1,234.50)	-123450.0%
Fair Value	-6.21 - -6.21	-6.21	-125.33%
P/E	(19.46) - (19.91)	(19.86)	-181.1%
EV/EBITDA	(8.48) - (9.71)	(9.06)	-137.0%
EPV	(2.98) - (3.92)	(3.45)	-114.1%
DDM - Stable	(17.22) - (103.30)	(60.26)	-346.0%
DDM - Multi	(1,620.72) - (7,611.99)	(2,679.27)	-11035.8%